• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Iconovo

1.05 SEK-2.78 %15.7, 17.25
Less than 1K followers

ICO

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-2.78 %
-13.58 %
-8.30 %
-12.50 %
-7.89 %
-50.24 %
-95.42 %
-98.53 %
-96.78 %

Iconovo operates in the medical technology sector. The company develops inhalers for medical use. The company's products are used in the treatment of asthma and coal, where the inhalers consist of powder-based medicine. The products are licensed and sold under various brands. In addition to product development, there is expertise in pharmaceutical formulation. The company was founded in 2013 and has its headquarters in Lund.

Read more
Market cap
100.98M SEK
Turnover
8.72K SEK
Revenue
1.11M
EBIT %
-3,883.78 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
20.8
2026

Interim report Q2'26

23.10
2026

Interim report Q3'26

26.2
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release03.07.2026, 12.40

Iconovo AB (publ) reintroduces liquidity provider agreement with Pareto Securities AB

Iconovo
Regulatory press release29.06.2026, 14.00

Iconovo terminates liquidity provider agreement

Iconovo
Press release22.06.2026, 08.30

Iconovo and Lonza sign Strategic Collaboration Agreement

Iconovo

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release24.04.2026, 17.52

DNB Carnegie Access: Iconovo: Limited progress – Q1 review

Iconovo
Regulatory press release24.04.2026, 08.30

QUARTERLY REPORT Q1 2026

Iconovo
Regulatory press release14.04.2026, 15.40

Anders Månsson is appointed CEO

Iconovo
Regulatory press release17.03.2026, 16.05

Iconovo publishes outcome of exercise of warrants series TO 1

Iconovo
Regulatory press release10.03.2026, 08.05

Iconovo’s rights issue is registered – conversion of BTA into shares

Iconovo
Regulatory press release02.03.2026, 16.20

Iconovo announces final outcome in the rights issue

Iconovo
Regulatory press release27.02.2026, 18.20

Iconovo publishes preliminary outcome of rights issue and announces recalculation of warrants series TO 1

Iconovo
Press release24.02.2026, 20.50

Iconovo and Lonza signs LOI regarding strategic collaboration

Iconovo
Press release16.02.2026, 19.01

DNB Carnegie Access: Iconovo: Still needs proof – Q4 review

Iconovo
Press release13.02.2026, 14.45

DNB Carnegie Access: Iconovo - Q4 2025 - Intervju

Iconovo
Regulatory press release13.02.2026, 08.30

The subscription period in Iconovo's rights issue begins today

Iconovo
Regulatory press release12.02.2026, 14.30

Iconovo publishes information document regarding rights issue of shares

Iconovo
Regulatory press release12.02.2026, 08.30

Year-end report 1 January - 31 December 2025

Iconovo
Press release15.01.2026, 10.15

Iconovo has initiated a new feasibility study for ICOone® Nasal in collaboration with multinational company

Iconovo
Press release13.01.2026, 13.40

EPO declares intention to approve ICOpre® patent application

Iconovo
Regulatory press release22.12.2025, 10.00

Nomination Committee appointed at Iconovo AB

Iconovo
Regulatory press release16.12.2025, 12.45

Iconovo announces that the terms and conditions for allotment of shares in directed issue are met

Iconovo